Severe acute respiratory syndrome coronavirus 2 nucleocapsid protein messenger RNA (SARS-CoV-2 N mRNA)

The Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein messenger RNA (mRNA) is the genetic template for the synthesis of the N protein, which is vital for the viral life cycle (Source: UniProt P0DTC9). The N protein functions by binding to the viral RNA genome to form the ribonucleoprotein complex, facilitating genome packaging into new virions and supporting viral RNA replication (Source: PubMed: 32358203). Because the N gene sequence is highly conserved across various SARS-CoV-2 variants and other betacoronaviruses, its mRNA represents a stable and effective target for sequence-specific therapeutics (Source: Nature Communications, 2021, 12:2977). Therapeutic strategies targeting this mRNA include small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs), which are designed to induce the degradation of the transcript or inhibit its translation (Source: NIH, PMC7355128). For example, the investigational drug VIR-2703 (ALN-COV) utilizes the RNA interference (RNAi) pathway to silence the N gene, thereby reducing viral replication and potentially mitigating the severity of COVID-19 (Source: Alnylam Pharmaceuticals). This approach is particularly advantageous as it targets a site less prone to the mutational escape observed in the spike protein (Source: PubMed: 33851094). Furthermore, targeting the N mRNA can be combined with other antiviral strategies to provide a multi-pronged defense against the virus. Monitoring the levels of this mRNA in clinical samples serves as a key diagnostic and prognostic indicator for the progression of the infection.

Other names

SARS-CoV-2 nucleocapsid gene transcriptSARS-CoV-2 N gene mRNA2019-nCoV N protein mRNANucleocapsid phosphoprotein mRNA

RNA interference (RNAi) mediated degradation, antisense-mediated RNase H cleavage, and translation inhibition